Revealing targeted therapy for human cancer by gene module maps

Area of Science:

• Genomics
• Cancer Biology
• Molecular Medicine

Background:

• Cancer research aims to match therapies to molecular targets.
• Genome-scale expression profiling identifies cancer subtypes and improves prognoses.
• Effective treatments for newly identified genetic cancer subtypes remain unknown.

Purpose of the Study:

• To demonstrate that gene module maps can guide the identification of targeted therapies for cancer subtypes.
• To reveal specific functional pathways in cancer subtypes susceptible to targeted therapies.
• To translate complex genomic signatures into targeted therapeutic strategies.

Main Methods:

• Visualizing genome-scale gene expression as activated/deactivated functional modules (gene module maps).
• Analyzing human breast cancer gene expression data, focusing on a
• wound signature
• mitochondria gene module
• and proteasome gene module.
• Testing the efficacy of 3-bromopyruvic acid (glycolysis inhibitor) and bortezomib (proteasome inhibitor) on breast cancer cells.

Main Results:

• Activation of a poor-prognosis "wound signature" in breast cancer correlates with induced mitochondria and proteasome gene modules.
• 3-bromopyruvic acid selectively killed breast cancer cells exhibiting the mitochondria and wound signatures.
• Bortezomib inhibited wound signature expression and selectively killed breast cancer cells with this signature.

Conclusions:

• Gene module maps can prospectively identify targeted therapies for genetic cancer subtypes.
• Targeted therapies like 3-bromopyruvic acid and bortezomib show selective efficacy against specific cancer subtypes.
• Gene module maps offer a pathway for translating genomic findings into clinical cancer therapies.